Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Anti-atherosclerotic therapies: Milestones, challenges, and emerging innovations

Molecular Therapy(2022)10.1016/j.ymthe.2022.08.024Source: DataRank Database

Anti-atherosclerotic therapies: Milestones, challenges, and emerging innovations is a research paper published in Molecular Therapy (2022). On theSindex it has a DataRank of 0. It has been cited 102 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access102 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 18.70)OA: greenTopics (52)IDs (PubMed, PMC, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (2)

Hana Totary-Jain ORCID,Isabella Hetherington ORCID

Live enrichment

PubMed:36065464 PMC:PMC9552812 OpenAlex:https://openalex.org/W4294983234

National Institutes of Health

Grant: R01 HL128411

National Institutes of Health

Grant: 5R01HL128411-08

Cell-Selective Therapies for Coronary Artery Disease

FWCI

18.70

Citation Percentile

1.0%

Citation Trend

2023

2024

2025

2026

greenLicense: cc-by-nc-nd

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/9552812

publisherhttps://api.elsevier.com/content/article/PII:S1525001622005536?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1525001622005536?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.ymthe.2022.08.024

Fields of Study

Coronary Interventions and DiagnosticsLipoproteins and Cardiovascular HealthAtherosclerosis and Cardiovascular Diseases0301 basic medicine03 medical and health sciences0302 clinical medicineAtherosclerosisDrug-Eluting StentsGlucoseHumansLipidsRNA, MessengerRisk FactorsTreatment Outcome

MeSH Terms

GlucoseHumansLipidsRisk FactorsRNA, MessengerTreatment OutcomeAtherosclerosisDrug-Eluting Stents

Keywords

MedicineMyocardial infarctionIntensive care medicineStroke (engine)DiseaseCause of deathPercutaneous coronary interventionCardiologyRevascularizationCoronary artery diseaseInternal medicineBioinformaticsAtherosclerosisInflammationCardiovascular diseaseStrokeNanomedicinePrecision MedicineNanotherapyBase EditingMrna TherapeuticsMirna-switchGlucoseTreatment OutcomeRisk FactorsHumansDrug-Eluting StentsReviewRNA, MessengerLipids

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being